Literature DB >> 8635291

Nonprecipitating anti-La(SS-B) autoantibodies in primary Sjögren's syndrome.

R G Beer1, M Rischmueller, T Coates, A W Purcell, C L Keech, J McCluskey, T P Gordon.   

Abstract

Anti-La(SS-B) precipitin-negative sera show a restricted epitope recognition and can be easily overlooked in routine laboratory testing. We have therefore determined the prevalence of nonprecipitating anti-La(SS-B) antibodies in patients with primary Sjögren's syndrome and studied their clinical and immunological associations. Clinical details were obtained from 68 patients with primary Sjögren's syndrome, and serum samples were examined by enzyme-linked immunosorbent assay using purified recombinant La, 60-kDa Ro, and 52-kDa Ro proteins and by counterimmunoelectrophoresis. Thirteen patients (19%) were identified with anti-La antibodies which were nonprecipitating. These patients had similar clinical findings to other groups of patients with Sjogren's syndrome, but had significantly lower rheumatoid factor and serum IgG levels than patients with anti-La precipitins. None of the patients with nonprecipitating anti-La antibodies had previously contained anti-La precipitins in their sera. Furthermore, they tended to have lower levels of antibodies directed against denatured 60-kDa Ro (but not 52-kDa Ro) compared with anti-La precipitin-positive patients. Patients with Sjögren's syndrome associated with nonprecipitating anti-La antibodies represent a stable serological and clinical subset in which there appears to be limited diversification of the autoimmune response to the Ro60 and La proteins of the Ro/La ribonucleoprotein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635291     DOI: 10.1006/clin.1996.0084

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  6 in total

1.  HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren's syndrome (pSS).

Authors:  M Rischmueller; S Lester; Z Chen; G Champion; R Van Den Berg; R Beer; T Coates; J McCluskey; T Gordon
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

2.  Characterization of human telomerase complex.

Authors:  S Ramakrishnan; H W Sharma; A D Farris; K M Kaufman; J B Harley; K Collins; G J Pruijn; W J van Venrooij; M L Martin; R Narayanan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  Cross-recognition between histones and La/SSB may account for anti-DNA reactivity in SLE patients.

Authors:  E Touloupi; J G Routsias; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

4.  Anti-alpha-fodrin antibodies do not add much to the diagnosis of Sjögren's syndrome.

Authors:  Michiel M Zandbelt; Judith Vogelzangs; Leo BA Van De Putte; Walther J Van Venrooij; Frank HJ Van Den Hoogen
Journal:  Arthritis Res Ther       Date:  2003-10-31       Impact factor: 5.156

5.  Epistasis between the MHC and the RCA alpha block in primary Sjögren syndrome.

Authors:  S Lester; C McLure; J Williamson; P Bardy; M Rischmueller; R L Dawkins
Journal:  Ann Rheum Dis       Date:  2007-09-18       Impact factor: 19.103

6.  Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome.

Authors:  Susan Lester; Leanne Stokes; Kristen K Skarratt; Ben J Gu; Kathy L Sivils; Christopher J Lessard; James S Wiley; Maureen Rischmueller
Journal:  Arthritis Res Ther       Date:  2013-06-02       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.